Clene

Clene Accounts Payable

The Accounts Payable of Clene (CLNN) as of Nov 16, 2026 is 892,000.00 USD. In the previous year, Accounts Payable was 1.24 M USD — a change of -28.06% (lower).

Accounts Payable

892,000.00USD

YoY

-28.06%

Last updated:

Accounts Payable of Clene is 2025 892,000.00 USD. Accounts Payable of Clene was 2024 1.24 M USD. It decreases by -28.06% lower compared to the previous year.

The Clene Accounts Payable history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Accounts Payable
Date
Accounts Payable
Jan 1, 2018
1.10 M USD
Jan 1, 2019
889,000.00 USD
Jan 1, 2020
1.12 M USD
Jan 1, 2021
1.92 M USD
Jan 1, 2022
3.01 M USD
Jan 1, 2023
1.50 M USD
Jan 1, 2024
1.24 M USD
Jan 1, 2025
892,000.00 USD
The Clene Accounts Payable history
YEARAccounts PayableYoY
892,000.00USD-28.06%
1.24 MUSD-17.55%
1.50 MUSD-50.10%
3.01 MUSD+56.73%
1.92 MUSD+71.09%
1.12 MUSD+26.43%
889,000.00USD-18.89%
1.10 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clene Stock analysis

What does Clene do? Clene Inc develops therapeutic products for neurodegenerative diseases, focusing on targeting energetic failure as a root cause. Its primary product CNM-Au8 is an oral suspension of gold nanocrystals designed to restore neuronal health by enhancing energy production and utilization. The company also develops CNM-ZnAg, a spectrum antiviral and antibacterial agent containing zinc and silver ions for infectious disease treatment and immune support, and CNM-AgZn17, a gel polymer suspension of zinc and silver for wound healing and infectious disease management. These products are intended for clinical development and eventual commercialization in the pharmaceutical market. Clene's target customers are patients suffering from neurodegenerative diseases and infectious conditions requiring antiviral, antibacterial, or wound healing solutions. The company's products aim to address unmet medical needs in these therapeutic areas by leveraging innovative nanocrystal and ion-based technologies. The firm operates within the biopharmaceutical sector, developing treatments that focus on cellular energy processes to provide neuroprotection and remyelination. The company generates revenue through the development and potential future commercialization of its drug candidates. CNM-Au8 targets neurodegenerative diseases by addressing energetic failure, while CNM-ZnAg and CNM-AgZn17 focus on infectious disease treatment and wound healing applications. These products are in clinical development stages, with the company seeking to advance them toward regulatory approval and market entry. Clene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Clene stock

Accounts Payable of Clene is 892,000.00 USD in 2025.

Accounts Payable of Clene changed from 1.24 M USD to 892,000.00 USD, representing a -28.06% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Accounts Payable Clene since 2006 – with annual values, charts, and detailed analysis.

Accounts payable represents money owed to suppliers for goods and services received. It is a key component of working capital management.

Accounts Payable's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Payable's Clene historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Clene

All Key Metrics — Clene